MR-guided focused ultrasound (MRgFUS) developer InSightec has secured expanded insurance coverage for its MRgFUS device, Exablate Neuro.
The device enables treatment of essential tremor and tremor-dominant Parkinson's disease with incisionless surgery. It has been cleared by the U.S. Food and Drug Administration (FDA).
The new coverage comes from an agreement with Noridian Healthcare Solutions of Fargo, ND, a government healthcare contractor. Medicare beneficiaries in 38 U.S. states will now have coverage for the treatment, InSightec said.
